How can we help?

MAMMALIAN CELL TECHNOLOGY

Bioneer assists clients in the pre-clinical and early clinical phases with production of recombinant proteins in a variety of mammalian cell systems, with access to existing or development of novel functional assays based upon mammalian cells as well as general technology development, e.g. bioreactor evaluation, biobanking, and cell handling. In fact, we can support our clients in the entire process of bringing a novel biologic compound from the laboratory through pre-clinical evaluation for functionality and safety.

IMMUNE TARGETING

Bioneer offers evaluation of compounds using mainly three cell systems 1) Primary dendritic cells (human and murine) 2) Peripheral blood mononuclear cells (PBMCs) and 3) cell line based models. We provide services in our model systems in the discovery process (mainly evaluation of mechanism of action and immune modulation and suppression of specific inflammatory responses) as well as activities involved in the development process (mainly evaluation of safety of IV administered drugs, and assessment of potency).

PROTEIN MANUFACTURING

Bioneer addresses a client's needs for limited amounts of recombinant proteins, e.g. during the discovery phase and preclinical phase of biologics development.

DRUG DEVELOPMENT

Turning an active compound into a drug product

Pharmaceutical services, covering the field from lead identification to final formulation of the active compound, are provided by Bioneer:FARMA.

Bioneer:FARMA is a business unit of Bioneer established in collaboration with the Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark.

BIOMARKERS

Bioneer offers a range of services related to the identification, validation and documentation of disease relevant biomarkers and drug targets. These services comprise a toolbox of molecular methods that will facilitate the pre-clinical development of both biomarkers, drug-targets and active compounds, which will be useful in diagnostic, prognostic, and therapeutic contexts, and, furthermore, serve as effective means to optimize clinical trial designs.

DYNAMIC GASTRIC MODEL

The Dynamic Gastric Model is the first true "dynamic" in-vitro model of the human stomach that fully replicates the complex biochemical conditions and the array of gastric forces crucial for the prediction of oral pharmaceuticals and food products

News:

2016-09-14:
Bioneer seeks a new Protein Chemist
New attractive position at Bioneer for an experienced protein chemist or like in the area of downstream processing and protein characterization.
Read more
2016-08-30:
Søren Carlsen joins Bioneer as Director of the Board

Bioneer welcomes Søren Carlsen as new Director of the Board. Thereby the Board includes an experienced and well-recognized person, who knows the Danish Life Science industry inside out.

Read more
2016-08-30:
New P-glycoprotein cell line to predict blood brain barrier permeability of drugs

Bioneer offers a new service to assess the permeability of a drug across the blood-brain barrier. The cell line is characterized by producing large amounts of P-glycoprotein.

Read more
READ MORE NEWS

Meet us at:

ESMO Oncology conference Copenhagen 2016

Meet Boye Schnack Nielsen and Kim Holmstrøm who are actively involved in clinical biomarker research at ESMO October 7th - 11th 2016. They can tell you more about the detection and molecular pathology services of Bioneer. 

Read more
Symposium on Biorelevant assays

Bioneer:FARMA presents “In vitro lipid digestion models” in London Oct 5th 2016 

Read more
Bioneer @ CPHI Barcelona Oct 4 - 6 2016
Bioneer will be exhibiting at CPhI, 4-6th Oct., 2016 in Barcelona – come meet us there !
Read more
Other places to meet us